NEW YORK (GenomeWeb News) – Shares of Exact Sciences today fell as much as 30 percent after the company announced top-line data from a pivotal clinical trial for its colorectal cancer screening test.

Amid heavy trading, shares of the Madison, Wis.-based firm dipped to as low as $6.93 from Wednesday's closing price of $9.97, after results from the trial, called DeeP-C, failed to meet some internal targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.